Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .
Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial.
PURPOSE In a r and omized clinical trial in patients with advanced non-small-cell lung cancer ( NSCLC ) , infusion with adenosine 5'-triphosphate ( ATP ) inhibited loss of body weight and quality of life . In the present article , the effects of ATP on body composition , energy intake , and energy expenditure as secondary outcome measures in the same patients are reported . PATIENTS AND METHODS Patients with NSCLC , stage IIIB or IV , were r and omized to receive either 10 intravenous , 30-hour ATP infusions every 2 to 4 weeks or no ATP .  Fat mass ( FM ) , fat-free mass ( FFM ) , and arm muscle area were assessed at 4-week intervals for 28 weeks . Food intake , body cell mass ( BCM ) , and resting energy expenditure ( REE ) were assessed at 8-week intervals for 16 weeks . Between-group differences were tested for statistical significance by repeated- measures analysis of covariance . RESULTS Fifty-eight patients were r and omized ( 28 ATP , 30 control ) . No change in body composition over the 28-week follow-up period was found in the ATP group , whereas , per 4 weeks , the control group lost 0.6 kg of FM ( P = .004 ) , 0.5 kg of FFM ( P = .02 ) , 1.8 % of arm muscle area ( P = .02 ) , and 0.6 % of BCM/kg body weight ( P = .054 ) and decreased 568 KJ/d in energy intake ( P = .0001 ) . Appetite also remained stable in the ATP group but decreased significantly in the control group ( P = .0004 ) . No significant differences in REE between the ATP and control groups were observed . CONCLUSION The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues . These effects are partly ascribed to maintenance of energy intake
Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .